Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,378 across all filing types
Latest filing 2019-05-24 Declaration of Voting R…
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
ANNOUNCEMENT IN RELATION TO THE RESOLUTIONS PASSED AT THE 2018ANNUAL GENERAL MEETING
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement regarding the resolutions passed at the 2018 Annual General Meeting (AGM) of Yanzhou Coal Mining Company Limited. It details the date and venue of the AGM, attendance, voting results on various resolutions including approval of financial statements, dividend distribution, amendments to articles of association, and other corporate matters. The document is not the full annual report or financial statements but a formal announcement of the AGM outcomes and voting results. It includes detailed voting percentages and resolutions passed, which is typical for a Declaration of Voting Results & Voting Rights Announcements document. The length of the document (15,000 characters) and the content focusing on resolutions and voting results further support this classification. Therefore, the appropriate filing type is DVA (Declaration of Voting Results & Voting Rights Announcements).
2019-05-24 English
VOLUNTARY ANNOUNCEMENT - CSTONE'S PARTNER AGIOS ANNOUNCES THE PHASE 3 CLARIDHY TRIAL OF TIBSOVO (IVOSIDENIB) ACHIEVED ITS PRIMARY RESULT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals regarding the Phase 3 clinical trial results of a drug (TIBSOVO) developed by its partner Agios Pharmaceuticals. It discusses clinical trial outcomes, future plans for drug application submission, and company background. There are no financial statements, regulatory certifications, or detailed financial data. The document is an announcement of clinical trial results and future plans, not a financial report or regulatory filing. It is not a report publication announcement since it does not mention the release or availability of a report but rather announces trial results and plans. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2019-05-23 English
FORM OF PROXY FOR ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Form of Proxy' for the Annual General Meeting (AGM) of CStone Pharmaceuticals. It includes instructions for shareholders to appoint proxies to vote on various resolutions at the AGM, including receiving the audited financial statements, re-electing directors, appointing auditors, and authorizing share allotments and repurchases. This type of document is typically distributed to shareholders prior to the AGM to facilitate voting and is not the AGM presentation materials themselves, nor the actual voting results or the annual report. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings.
2019-05-21 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 95% confidence The document is a notice of the Annual General Meeting (AGM) for CStone Pharmaceuticals, detailing the date, location, agenda items including re-election of directors, approval of financial statements, appointment of auditors, and share issuance and repurchase mandates. It is clearly labeled as a "NOTICE OF ANNUAL GENERAL MEETING" and contains no actual financial statements or detailed financial analysis, but rather the meeting agenda and resolutions to be voted on. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM. The document length is substantial (14,700 characters), consistent with a full AGM notice rather than a brief announcement. Therefore, the correct classification is AGM-R with high confidence.
2019-05-21 English
PROPOSALS FOR GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES, RE-ELECTION OF RETIRING DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 100% confidence The document is a circular from the board of CStone Pharmaceuticals dated May 21, 2019, containing detailed proposals for general mandates to issue and repurchase shares, re-election of retiring directors, and a notice of the Annual General Meeting (AGM) scheduled for June 20, 2019. It includes a letter from the board, explanatory statements, biographical details of directors proposed for re-election, and the formal notice of the AGM. The content is focused on governance matters and shareholder meeting arrangements rather than financial results or audit information. The document is lengthy (15,000 characters) and contains the full notice and related materials for the AGM, not just an announcement or a proxy form. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting.
2019-05-21 English
VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES FIRST PATIENT DOSED IN CHINA FOR GLOBAL PHASE I CLINICAL TRIAL OF FGFR4 INHIBITOR BLU-554 (CS3008)
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals about dosing the first patient in China for a global Phase I clinical trial of a drug candidate. It contains no financial data, no regulatory filings, no voting results, no management changes, no earnings or annual report content. It is a corporate announcement about clinical trial progress, which is a typical type of regulatory announcement but does not fit into financial report categories. The document is about a clinical trial milestone and does not contain financial statements or detailed financial analysis. Therefore, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2019-05-20 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.